



# COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

## DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid  
Drug Utilization Review (DUR) Board  
2:00pm  
Thursday, August 20, 2015  
DMAS Board Room 13<sup>th</sup> Floor

### Agenda

1. **Call to Order and Introductions** – Randy Ferrance, MD, Chair
2. **Minutes**
  - a. Approval of Minutes from November 20, 2014 meeting
3. **New Drugs**
  - a. **May Binder**
    - i. Contrave<sup>®</sup> (naltrexone/bupropion)
    - ii. Esbriet<sup>®</sup> (pirfenidone)
    - iii. Ofev<sup>®</sup> (nintedanib)
    - iv. Lynparza<sup>™</sup> (olaparib)
    - v. Soolantra<sup>®</sup> (ivermectin)
    - vi. Tybost<sup>®</sup> (cobicistat)
    - vii. Evotaz<sup>™</sup> (atazanavir sulfate/cobicistat)
    - viii. Prezcobix<sup>™</sup> (darunavir/cobicistat)
    - ix. Vitekta<sup>®</sup> (elvitegravir)
    - x. Farydak<sup>®</sup> (panobinostat)
    - xi. Ibrance<sup>®</sup> (palbociclib)
    - xii. Lenvima<sup>™</sup> (lenvatinib)
    - xiii. New drugs: PDL-eligible; physician-administered injectables
  - b. **August Binder**
    - i. Corlanor<sup>®</sup> (ivabradine)
    - ii. Jadenu<sup>™</sup> (deferasirox)
    - iii. Natpara<sup>®</sup> (parathyroid hormone)
    - iv. Orkambi<sup>™</sup> (lumacaftor/ivacaftor)
    - v. Saxenda<sup>®</sup> (liraglutide)
    - vi. New drugs: PDL-eligible; physician-administered injectables



# COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

## DRUG UTILIZATION REVIEW PROGRAM

4. **Service Authorizations**
  - a. **May Binder**
    - i. Jakafi – new FDA approved indication for polycythemia vera
    - ii. Kalydeco – now approved for patients age 2 years and older with specific gene mutations; new granule formulation
    - iii. Imbruvica – now approved for Waldenström’s macroglobulinemia
  - b. **August Binder**
    - i. Promacta – now approved for patients age 6 years and older with chronic immune idiopathic thrombocytopenia (ITP)
5. **Reports**
  - a. **May Binder**
    - i. ProDUR
    - ii. RetroDUR
    - iii. Utilization Analysis
    - iv. Top Diagnoses by Age
    - v. AAP Report
  - b. **August Binder**
    - i. ProDUR
    - ii. RetroDUR
    - iii. Utilization Analysis
    - iv. Top Diagnoses by Age
    - v. AAP Report
6. **Topics for Discussion**
  - a. **May Binder**
    - i. Analysis of Compounded Medications – *follow up*
    - ii. Morphine Equivalent Dosing for Narcotics
    - iii. Synagis<sup>®</sup> utilization
  - b. **August Binder**
    - i. New DUR Quarterly Newsletter - *draft*
7. First Data Bank’s *Alert Space* Clinical Modules (May Binder)
8. Other Business
9. Adjournment